Latest period
$20.1B
YoY change
+13.1%
5Y CAGR
-13.4%
Peak year (FY2019)
$51.6B
Latest annual
$18.5B
Total Equity history chart for Bristol-Myers Squibb (BMY) from 2016 to 2025
Latest: $18.5B
Total Equity growth chart for Bristol-Myers Squibb (BMY) from 2016 to 2025
Latest: +13.1%
Total Equity history table for Bristol-Myers Squibb (BMY) from 1987 to 2025
| FY2025 | $18.5B | +13.1% | +$2.14B | ||
| FY2024 | $16.3B | -44.5% | -$13.1B | ||
| FY2023 | $29.4B | -5.3% | -$1.63B | ||
| FY2022 | $31.1B | -13.6% | -$4.89B | ||
| FY2021 | $35.9B | -5.0% | -$1.88B | ||
| FY2020 | $37.8B | -26.7% | -$13.8B | ||
| FY2019 | $51.6B | +267.7% | +$37.6B | ||
| FY2018 | $14B | +19.5% | +$2.29B | ||
| FY2017 | $11.7B | -27.4% | -$4.44B | ||
| FY2016 | $16.2B | +13.4% | +$1.91B | ||
| FY2015 | $14.3B | -3.9% | -$586M | ||
| FY2014 | $14.9B | -2.0% | -$302M | ||
| FY2013 | $15.2B | +11.2% | +$1.53B | ||
| FY2012 | $13.6B | -14.6% | -$2.33B | ||
| FY2011 | $16B | +1.5% | +$243M | ||
| FY2010 | $15.7B | +5.9% | +$870M | ||
| FY2009 | $14.8B | +21.3% | +$2.6B | ||
| FY2008 | $12.2B | +15.9% | +$1.68B | ||
| FY2007 | $10.6B | +5.7% | +$571M | ||
| FY2006 | $9.99B | -10.9% | -$1.22B | ||
| FY2005 | $11.2B | +9.9% | +$1.01B | ||
| FY2004 | $10.2B | +4.3% | +$416M | ||
| FY2003 | $9.79B | +11.8% | +$1.03B | ||
| FY2002 | $8.76B | -3.5% | -$319M | ||
| FY2001 | $9.08B | -1.1% | -$105M | ||
| FY2000 | $9.18B | +6.2% | +$535M | ||
| FY1999 | $8.65B | +14.1% | +$1.07B | ||
| FY1998 | $7.58B | +4.9% | +$357M | ||
| FY1997 | $7.22B | +9.9% | +$649M | ||
| FY1996 | $6.57B | +12.8% | +$748M | ||
| FY1995 | $5.82B | +2.1% | +$118M | ||
| FY1994 | $5.7B | -4.0% | -$236M | ||
| FY1993 | $5.94B | -1.3% | -$80M | ||
| FY1992 | $6.02B | +3.9% | +$225M | ||
| FY1991 | $5.8B | +7.0% | +$377M | ||
| FY1990 | $5.42B | +6.6% | +$334M | ||
| FY1989 | $5.08B | +2.7% | +$136M | ||
| FY1988 | $4.95B | +4.1% | +$193M | ||
| FY1987 | $4.76B | — | — |
- FY2025$18.5B+13.1%
- FY2024$16.3B-44.5%
- FY2023$29.4B-5.3%
- FY2022$31.1B-13.6%
- FY2021$35.9B-5.0%
- FY2020$37.8B-26.7%
- FY2019$51.6B+267.7%
- FY2018$14B+19.5%
- FY2017$11.7B-27.4%
- FY2016$16.2B+13.4%
- FY2015$14.3B-3.9%
- FY2014$14.9B-2.0%
- FY2013$15.2B+11.2%
- FY2012$13.6B-14.6%
- FY2011$16B+1.5%
- FY2010$15.7B+5.9%
- FY2009$14.8B+21.3%
- FY2008$12.2B+15.9%
- FY2007$10.6B+5.7%
- FY2006$9.99B-10.9%
- FY2005$11.2B+9.9%
- FY2004$10.2B+4.3%
- FY2003$9.79B+11.8%
- FY2002$8.76B-3.5%
- FY2001$9.08B-1.1%
- FY2000$9.18B+6.2%
- FY1999$8.65B+14.1%
- FY1998$7.58B+4.9%
- FY1997$7.22B+9.9%
- FY1996$6.57B+12.8%
- FY1995$5.82B+2.1%
- FY1994$5.7B-4.0%
- FY1993$5.94B-1.3%
- FY1992$6.02B+3.9%
- FY1991$5.8B+7.0%
- FY1990$5.42B+6.6%
- FY1989$5.08B+2.7%
- FY1988$4.95B+4.1%
- FY1987$4.76B—
Total Equity values are taken from Bristol-Myers Squibb's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Bristol-Myers Squibb (BMY)
According to Bristol-Myers Squibb's latest reported financial statements, the company's latest reported total equity is $20.1B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Bristol-Myers Squibb (BMY) total equity is $18.5B – grew 13.1% year-over-year.
Through 2020–2025 (5 years), Bristol-Myers Squibb total equity delivered a -13.4% annualised rate; with a net decline across the window.
Bristol-Myers Squibb total equity peaked at $51.6B in 2019; the latest annual figure is $18.5B in 2025 (64.2% below peak).
Across the available history, total equity reached its high of $51.6B in 2019 and its low of $4.76B in 1987.
Bristol-Myers Squibb Total Equity by Year
Bristol-Myers Squibb Total Equity 2025: $18.5B
In 2025, Bristol-Myers Squibb reported total equity of $18.5B, grew 13.1% from 2024.
Bristol-Myers Squibb Total Equity 2024: $16.3B
Bristol-Myers Squibb total equity in 2024 was $16.3B, plunged 44.5% below 2023.
Bristol-Myers Squibb Total Equity 2023: $29.4B
2023's total equity for Bristol-Myers Squibb came in at $29.4B, declined 5.3% below 2022.
Bristol-Myers Squibb Total Equity 2022: $31.1B
Bristol-Myers Squibb posted total equity of $31.1B in 2022, declined 13.6% below 2021.
Bristol-Myers Squibb Total Equity 2021: $35.9B
Bristol-Myers Squibb total equity in 2021 was $35.9B.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers by Total Equity
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest total equity
| $94.1B | |
| $81.5B | |
| $53.4B | |
| $52.6B | |
| $30.5B | |
| $26.5B | |
| $8.66B | |
| -$3.27B |
- $94.1B
- $81.5B
- $52.6B
- $30.5B
- $26.5B
- $8.66B
- -$3.27B
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.08% TTM
- Dividend Profile4.13% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.